GKOS Short Volume
Glaukos Corporation (GKOS) operates in the Healthcare sector, specifically the Medical - Devices industry, with a market capitalization near $8.06B, listed on NYSE, employing roughly 995 people, carrying a beta of 0.95 to the broader market. Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Led by Thomas William Burns, public since 2015-06-25.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-05-15
- Short Volume
- 244.4K
- Total Volume
- 359.7K
- Short %
- 67.94%
- 30-Day Avg Short %
- 60.81%
Showing 30 days of FINRA short volume data for Glaukos Corporation.
Learn how short volume is reported and how to read the data →
Frequently asked GKOS short volume questions
- What is the daily GKOS short volume?
- As of May 15, 2026, Glaukos Corporation (GKOS) short volume is 244.4K shares against 359.7K total reported volume, or 67.94% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is GKOS short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does GKOS short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.